E Morrison1, D Crosbie, H A Capell. 1. Department of Rheumatology, Southern General Hospital, South Glasgow University Hospitals NHS Trust, UK. elaine.morrison@SGH.scot.nhs.uk
Abstract
OBJECTIVE: To assess the attitudes of rheumatoid arthritis (RA) patients to oral corticosteroid treatment, factors influencing these views and their likely clinical impact. METHODS: A cross-sectional survey of 158 consecutive RA out-patients was carried out at two centres over 2 weeks. Demography, disease duration, function [Health Assessment Questionnaire (HAQ)], erythrocyte sedimentation rate (ESR), years of formal education and social deprivation index were noted. Prospective recruitment into the multicentre West of Scotland Early Rheumatoid Arthritis Corticosteroid Trial (WOSERACT) was monitored and reasons for refusal to participate (when available) were noted at three of the centres. RESULTS: Forty-eight (32%) patients were willing to be treated with oral corticosteroid and 100 (68%) were not. The former were older (P = 0.002), had a higher ESR (P = 0.007), poorer function (P = 0.001) and greater previous exposure to disease-modifying anti-rheumatic drugs (P = 0.013). Ninety patients refused to participate in WOSERACT, in 46 cases (40 female, 6 male) the reason being concerns about corticosteroids. CONCLUSIONS: This study shows a high level of concern about and refusal of corticosteroid treatment in RA, due mainly to patient concerns about adverse effects. Rheumatologists need to be aware of these attitudes as they are likely to affect prescribing.
OBJECTIVE: To assess the attitudes of rheumatoid arthritis (RA) patients to oral corticosteroid treatment, factors influencing these views and their likely clinical impact. METHODS: A cross-sectional survey of 158 consecutive RA out-patients was carried out at two centres over 2 weeks. Demography, disease duration, function [Health Assessment Questionnaire (HAQ)], erythrocyte sedimentation rate (ESR), years of formal education and social deprivation index were noted. Prospective recruitment into the multicentre West of Scotland Early Rheumatoid Arthritis Corticosteroid Trial (WOSERACT) was monitored and reasons for refusal to participate (when available) were noted at three of the centres. RESULTS: Forty-eight (32%) patients were willing to be treated with oral corticosteroid and 100 (68%) were not. The former were older (P = 0.002), had a higher ESR (P = 0.007), poorer function (P = 0.001) and greater previous exposure to disease-modifying anti-rheumatic drugs (P = 0.013). Ninety patients refused to participate in WOSERACT, in 46 cases (40 female, 6 male) the reason being concerns about corticosteroids. CONCLUSIONS: This study shows a high level of concern about and refusal of corticosteroid treatment in RA, due mainly to patient concerns about adverse effects. Rheumatologists need to be aware of these attitudes as they are likely to affect prescribing.
Authors: Zachary S Wallace; Tyler Harkness; Xiaoqing Fu; John H Stone; Hyon K Choi; Rochelle P Walensky Journal: Arthritis Care Res (Hoboken) Date: 2020-11 Impact factor: 4.794
Authors: Joanna C Robson; Jill Dawson; Peter F Cronholm; Susan Ashdown; Ebony Easley; Katherine S Kellom; Don Gebhart; Georgia Lanier; Nataliya Milman; Jacqueline Peck; Raashid A Luqmani; Judy A Shea; Gunnar Tomasson; Peter A Merkel Journal: Rheumatol Int Date: 2017-11-09 Impact factor: 2.631